These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 15890569)

  • 41. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
    Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
    Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
    Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
    Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
    Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
    Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
    Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
    Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
    J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.
    Smith BD; Smith GL; Carter D; DiGiovanna MP; Kasowitz KM; Sasaki CT; Haffty BG
    Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):780-5. PubMed ID: 11448349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
    Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
    Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients.
    Thøgersen VB; Sørensen BS; Poulsen SS; Orntoft TF; Wolf H; Nexo E
    Cancer Res; 2001 Aug; 61(16):6227-33. PubMed ID: 11507076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region.
    Spindler KL; Nielsen JN; Lindebjerg J; Brandslund I; Jakobsen A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):500-4. PubMed ID: 16757132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
    Matsubara J; Yamada Y; Nakajima TE; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Oncology; 2008; 74(1-2):76-83. PubMed ID: 18544998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical markers in urinary bladder carcinomas from paraffin-embedded archival tissue after storage for 5-70 years.
    Litlekalsoy J; Vatne V; Hostmark JG; Laerum OD
    BJU Int; 2007 May; 99(5):1013-9. PubMed ID: 17437436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
    Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
    Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.